Ironwood CFO Tom Graney leaves for Vertex

  • After three years on the job
  • Praise, thanks and good wishes for Graney
  • Gina Consylman taking over in the interim
  • Search for a successor

(exechange) — Cambridge, Massachusetts, September 06, 2017 — Tom Graney, finance chief of Ironwood, leaves. It is a change at short notice. As announced by Ironwood Pharmaceuticals, Inc. in a news release and in a regulatory filing published on Wednesday, September 06, 2017, Thomas (Tom) Graney, chief financial officer, leaves the drug manufacturer after three years on the job, effective September 13, 2017.

Among the 3,000 largest publicly held companies incorporated in the U.S. based on market capitalization, the average tenure of the CFOs who departed over the past twelve months was 5.6 years, according to data compiled by exechange.

Ironwood will undertake a search for a successor.

Graney’s duties are taken over in the interim by Gina Consylman, currently vice president of finance and chief accounting officer at Ironwood Pharmaceuticals, Inc.

Career change

The imminent management change is explained as follows. Ironwood said: “Tom Graney, chief financial officer (CFO) and senior vice president, finance and corporate strategy will leave the company, effective September 13, 2017, to pursue another opportunity.”

Graney will be CFO at Vertex

Vertex Pharmaceuticals Incorporated announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO).

Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice President and Chief Operating Officer Ian Smith.

Vertex Pharmaceuticals Incorporated announced the move on Wednesday, September 06, 2017.

Vertex is a biotechnology company.

“Step down”

Ironwood said: “On September 1, 2017, Thomas Graney notified Ironwood Pharmaceuticals, Inc. … that he will step down from his position as Chief Financial Officer and Senior Vice President, Finance and Corporate Strategy of the Company effective September 13, 2017.”

Chaired by Terrance G. McGuire

Ironwood Pharmaceuticals, Inc. is chaired by Terrance G. McGuire.

Terrance G. McGuire has served as a director since 1998 and as chair of the Company’s board since 2015.

CEO: Peter Hecht

Peter Hecht serves as CEO of Ironwood Pharmaceuticals, Inc. Peter Hecht has served as Ironwood’s CEO and a director since co‐founding the company in 1998.

On the job as CFO since 2014

Thomas Graney has been the Chief Financial Officer and Senior Vice President of Finance & Corporate Strategy at Ironwood Pharmaceuticals, Inc. since September 2014.

Tom Graney joined Ironwood in 2014, bringing experience in finance, accounting and corporate strategy gained during his 20 years of service with Johnson & Johnson and its affiliates.

He most recently served for four years as worldwide vice president of finance and chief financial officer of Johnson & Johnson’s Ethicon, a global leader in surgical medical devices.

In addition, Graney has extensive global experience that spans corporate development, commercial strategy, portfolio management and supply chain management.

A Chartered Financial Analyst charterholder, Graney serves on the board of directors of AC Immune SA, a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases, and holds a B.S. in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.

Read the full story in the exechange report 37.2017 ($).